131 related articles for article (PubMed ID: 11035346)
1. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
Gossmann A; Helbich TH; Mesiano S; Shames DM; Wendland MF; Roberts TP; Ferrara N; Jaffe RB; Brasch RC
Am J Obstet Gynecol; 2000 Oct; 183(4):956-63. PubMed ID: 11035346
[TBL] [Abstract][Full Text] [Related]
2. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H
Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648
[TBL] [Abstract][Full Text] [Related]
3. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.
Nagy JA; Masse EM; Herzberg KT; Meyers MS; Yeo KT; Yeo TK; Sioussat TM; Dvorak HF
Cancer Res; 1995 Jan; 55(2):360-8. PubMed ID: 7812969
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
Luo JC; Toyoda M; Shibuya M
Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
8. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study of anti-vascular endothelial growth factor hairpin ribozyme gene inhibiting growth of xenografted tumor of ovarian cancer cells].
Yan R; Xin X; Jin M; Hui H; Wang J; Wang D
Zhonghua Fu Chan Ke Za Zhi; 2002 Nov; 37(11):683-6. PubMed ID: 12487926
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
13. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study of anti-VEGF hairpin ribozyme gene inhibiting expression of VEGF and proliferation of ovarian cancer cells].
Yan RL; Qian XH; Xin XY; Jin M; Hui HX; Wang DT; Wang J
Ai Zheng; 2002 Jan; 21(1):39-44. PubMed ID: 12500395
[TBL] [Abstract][Full Text] [Related]
15. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.
Graff BA; Bjørnaes I; Rofstad EK
Microvasc Res; 2001 Mar; 61(2):187-98. PubMed ID: 11254398
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
Dafni H; Israely T; Bhujwalla ZM; Benjamin LE; Neeman M
Cancer Res; 2002 Nov; 62(22):6731-9. PubMed ID: 12438274
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor.
Pham CD; Roberts TP; van Bruggen N; Melnyk O; Mann J; Ferrara N; Cohen RL; Brasch RC
Cancer Invest; 1998; 16(4):225-30. PubMed ID: 9589031
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer.
Liu CD; Tilch L; Kwan D; McFadden DW
J Surg Res; 2002 Jan; 102(1):31-4. PubMed ID: 11792148
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
20. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
